HER2 was a well clinically validated activating oncogenic driver in NSCLC, however, treatments targeting HER2 lead to mixed results.17–21 No HER2-targeted therapies were approved for NSCLC until the advent of T-DXd. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.